For instance, in a clinical trial on pembrolizumab monotherapy for PCa, Antonarakis, and others found that men with BRCA1/2 or ATM mutations had an objective response rate of 12%, which was much greater compared to the 4% objective response rate seen in men with no those mutations (Antonarakis et al., 2020). The gene discussed is ATM; the disease is posterior cortical atrophy.